Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Would you offer neoadjuvant chemotherapy to a patient with muscle-invasive enteric adenocarcinoma of the bladder?
If offering neoadjuvant chemotherapy, which regimen would you use?
Related Questions
Are there scenarios where you would still prefer adjuvant nivolumab based on known pathologic risk over using perioperative durvalumab for patients with muscle invasive bladder cancer?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?
What is your preferred treatment for a patient with refractory metastatic upper tract urothelial carcinoma previously treated with adjuvant gemcitabine/cisplatin, enfortumab vedotin + pembrolizumab, docetaxel and sacituzumab govitecan?
For neoadjuvant treatment of muscle invasive bladder cancer, are you utilizing durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
Do the results of IMvigor011 influence you to utilize ctDNA to guide all adjuvant IO in MIBC?
How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
Do you plan to extrapolate from the NIAGARA trial regarding peri-operative durvalumab/cis/gem to treat upper tract urothelial carcinoma?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?